According to a recent diabetes news report, anti- cholesterol drug fenofibrate could dramatically lower the risk of people with diabetes facing amputation, by as much as 36 per cent in some instances.
A special diabetes edition of The Lancet published the study, which was conducted in Australia. The 5-year trial involved almost 10,000 people with diabetes being given fenofibrate.
The team, from the National Health and Medical Research Council Clinical Trials Centre in the University of Sydney, Australia, reportedly commented: “Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations (below the ankle). These findings could lead to a change in standard treatment for the prevention of diabetes-related lower-limb amputations.”
Reports suggest that a diabetes related amputation happens every 30 seconds around the world.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…